|
A message from Porter & Company
I wish this wasn’t the case… But it’s happening, exactly as I predicted. I first warned my readers of this threat months ago. Many disregarded it. Now it’s accelerating and unless you prepare now you could be blindsided by an event two Nobel Prize winners have warned of… an event that you cannot ignore. The clock is ticking. Just take a look: In a single month, March of this year, U.S. employers announced 60,620 job cuts. That's a 25% jump from February. And one force was named as the reason why. Then the floodgates really opened. Meta announced it's laying off roughly 8,000 employees – 10% of its workforce – and quietly killing another 6,000 unfilled roles. The same week, Microsoft offered "voluntary separation" to 7% of its U.S. workers — more than 8,500 people. Translation: quit on your terms, or we'll fire you on ours. And they're not alone. Not by a long shot. Amazon cut 16,000 corporate jobs… Block cut 40% of its workforce…. Salesforce eliminated 44% of its support team... Oracle is reportedly axing up to 30,000 roles. IBM, Snap, Pinterest, Klarna… the list grows by the week. Almost 80,000 tech jobs evaporated in the first three months of 2026 alone. Although most people think this is about AI… it’s not. The story goes far deeper and is far more consequential. It’s something that I’ve been warning off for months now. And I’m not the only one. Two Nobel Prize winners have warned of this Final Displacement. Because they know, as I do, this event could trigger a once-in-a-generation wealth shift. A transfer of wealth that’s already begun with Goldman Sachs estimating 12,400 Americans are being financially destroyed every day… while others grow richer than ever before. Which side you’re on could depend on what you do next. Because for those who understand what’s unfolding, this could be one of the greatest wealth-building phenomena of their lives. But for those who bury their head in the sand… this force threatens to wipe out years of investment returns and could even destroy their financial future. Here’s the full story for you. 
26 years ago, I started telling friends, family, and anyone who would listen about an unprecedented societal shift that was barreling down on us. I’d discovered that a new technology was about to unleash massive, almost unimaginable, changes. I likened the impact to the railroad boom, the Industrial Revolution, and the rise of personal computing. At the time, I was working as an investment analyst for an elite research group, but my colleagues and bosses refused to listen to me. No matter what I said, they simply would not acknowledge the sands shifting beneath their feet. The legendary Dr. Kurt Richebächer – one of the world’s leading Austrian economists – even called me and my ideas “radical.” But I was certain this new technology would trigger a transformation that was simply unfathomable to most people… and those on the frontier could reap financial returns unlike any the world had ever seen before. So, I decided to put my entire career – not to mention every cent I had – on the line to spread the story myself. I left my job as a research analyst… went home to my third-floor apartment in one of Baltimore’s worst neighborhoods… and with a borrowed laptop, I wrote my first financial prophecy. And in an investment paper that’s now been read by more than one hundred thousand people… I explained how the endless miles of new fiber optic cables being laid was creating a new railroad across America. And that this new “railroad” was going to upend the telecommunications industry and pave the way for a new internet economy. I also warned it would decimate some of America's most dominant companies like AT&T. At the time, this was an outlandish idea, with analysts calling AT&T “dominant”, “unstoppable”, and “the giant that no other company can topple.” But those who were willing to open their minds to my so-called “radical” ideas were not only able to sell these companies before they collapsed… They also had the chance to get in early on the firms that would go on to command this new internet economy: Amazon, Adobe, Qualcomm, SunMicrosystems, Uniphase, Texas Instruments… These are household names now, but when I first recommended them in the late 90s, they were complete unknowns. Since then, I’ve issued a number of other financial prophecies, many of which have come to pass precisely as I predicted. But today, I’m stepping forward with a new exposé that I believe could surpass anything I’ve ever done… It’s an investigation into what I call The Final Displacement… and I don’t think we will ever again see a story that rivals the magnitude of this during my lifetime. I’m not talking about AI… quantum computing… augmented reality… the blockchain… or anything else you might be thinking of. No. This is far bigger than them all. In fact… It’s the cornerstone that all our recent technological innovations have been built upon and the future will be built upon too. Yet you’ve likely never heard of it before. Outside of the labs in the world’s most prestigious universities and tech companies, almost nobody has. But those who have… those who can see the writing on the wall… they’re investing billions of dollars, as they know this will transform everything. Marc Andreessen… Ben Horowitz… Elon Musk… Jeff Bezos… Mark Zuckerberg…Jensen Huang… Bill Gates… the list goes on and on. They know, as I do, that in a few years from now, we will not recognize the world we live in. How we work, live, communicate, transact… it will all be completely upended by what’s coming next. Today, I’m going to share it all with you… and I promise you’ve never heard anything like this before. You see, despite the magnitude of this story, nobody is openly and freely discussing this turning point. And that deeply concerns me, because I believe its emergence will draw an indelible demarcation line in society. On one side, you’ll have those who understand it, invest in it, and who are greatly enriched by it. On the other side… you’ll have those who underestimate it, turn a blind eye and are unfortunately impoverished by the sweeping changes it ushers in. I know what side I’ll be on. And I know what side I want you to be on. So go here to watch my full investigation into this story. Including the names of the companies to buy and sell if you want to capitalize on the impending multi-trillion-dollar displacement. Good investing, Porter Stansberry
Special Report
Viking Therapeutics Faces Timeline Risk—But Upside Could Be HugeAuthor: Chris Markoch. Posted: 5/1/2026. 
Key Points
- Viking Therapeutics stock reflects the long timelines of clinical-stage biotech, with key VK2735 trial results not expected until 2027.
- The company’s dual-track GLP-1 strategy, including injectable and oral drugs, positions it to compete in a fast-growing weight-loss market.
- Strong cash reserves support operations into 2028, but dilution risk and rising competition remain key concerns for investors.
- Special Report: NOT buy any SpaceX IPO shares until you read THIS
“Buy the story, sell the news” is a reasonable explanation for why Viking Therapeutics (NASDAQ: VKTX) fell more than 3% on the day the company delivered its Q1 2026 earnings report. For investors who may not be familiar with Viking Therapeutics, it’s important to understand that the company is not profitable and is still in the pre-revenue stage. So evaluating the earnings report on the headline numbers doesn’t work. Instead, because it’s a biotechnology company, investors will want to pay attention to where the company is in its FDA timeline to assess the risk and reward. The FDA process takes time, and that’s presenting investors with the possibility of a sizable long-term reward if they’re comfortable with near-term risk. Defining the Opportunity
Viking Therapeutics is a relatively new player in the GLP-1 space. The market is currently dominated by Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO). However, both companies are dealing with the challenge of scaling production to meet demand. That’s a good problem to have, but it’s one that leaves the door open for a company like Viking. That’s why investors are buying the story. Rather than being just another entrant into the GLP-1 space, Viking is taking a two-track approach that has the potential to set it apart from its competitors. This means advancing both an injectable (subcutaneous) and oral version of the drug through clinical trials. Progress Takes TimeCurrently, the injectable drug (VK2735) is further along in the process. The injectable formulation’s Phase 2 (VENTURE) trial was completed in 2025 and published in the peer-reviewed journal Obesity in January 2026. Viking has since reported that it has fully enrolled patients in the VANQUISH-1 trial, which covers adults with obesity, and the VANQUISH-2 trial, which covers adults with obesity and type 2 diabetes. These are 78-week trials, so investors shouldn’t expect results until the second half of 2027 at the earliest. But Viking is also making progress on the oral version of VK2735. The company completed an end-of-Phase 2 meeting with the FDA in December 2025 for the oral formulation, and based on the agency’s feedback, it plans to advance oral VK2735 into Phase 3. That’s not expected until Q4 2026, which puts it about six months behind the injectable version. The other issue with the time lag is that Viking doesn’t have the field to itself. Companies like Lilly already have oral pills in the market, and that could limit the addressable market even if Viking gets approved. Progress Takes MoneyIf successful, Viking will be able to enter the GLP-1 arena with two options, including an oral version that consumers have shown a preference for. But Viking will have to burn money to get the drugs through clinical trials. To that end, Viking ended the quarter with approximately $603 million. The company believes that amount is sufficient to carry it into 2028. That should be enough to get the injectable form of VK2735 through the clinical trial phase. To help mitigate execution risk, Viking has signed a comprehensive agreement with CordenPharma. However, the company did burn more cash than expected in the quarter, which may explain the selloff. If the company runs short of cash, it will likely need to raise capital through a share offering, which would be dilutive to shareholders. The Wildcard That Could Redefine the OpportunityIn addition to VK2735, Viking has also filed an investigational new drug (IND) application for its VK3019 candidate. This is a novel amylin agonist therapeutic that targets the amylin and calcitonin receptors, which play an important role in regulating food intake and metabolic control. Viking believes that dual activation of the amylin and calcitonin receptors could represent an attractive treatment option for patients who aren’t candidates for GLP-1 therapeutics. The company plans to initiate a Phase 1 trial in Q2 2026. How to Make Time Your Friend With VKTXRight now, short interest on VKTX is around 21%, and with 76% institutional ownership, that’s a headwind for retail investors. That’s evident with VKTX being down more than 14% in 2026 despite the encouraging progress. However, despite being a clinical-stage company, Viking has 13 analysts covering the stock, and they give it a consensus price target of $95.50. That implies a potential return of more than 200%. But with short-term volatility in place, this could be a time for investors to scale in over time. Using dollar-cost averaging or initiating a starter position and adding tranches based on the successful completion of milestones can help mitigate risk while still capturing upside. |
